NAFLD in Obese Chinese Patients Undergoing Bariatric Surgery
Official title: Clinical Course and Biomarkers Associated With Nonalcoholic Fatty Liver Disease (NAFLD) in Chinese Patients With Obesity
Run by Chinese University of Hong Kong · NCT07662356 · Data updated 2026-11-12
This study tests how NAFLD progresses and which biomarkers appear in obese Chinese adults undergoing laparoscopic bariatric surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong, New Territories) |
| Status | Recruiting |
| Started | December 16, 2019 |
| Main results expected | October 19, 2028 |
| Study ends | December 31, 2030 |
| Registry record updated | June 23, 2026 |
| Trial ID | NCT07662356 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years or older, of Chinese ethnicity, undergoing obesity surgery at Prince of Wales Hospital, with or without known NAFLD at baseline.
✕Probably not a fit
Patients with alcohol-related liver disease, other liver conditions, or those unwilling to consent may not benefit from the study findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study follows Chinese adults with obesity who are undergoing laparoscopic bariatric surgery to explore the clinical course of NAFLD and related biomarkers. Liver biopsies are taken during surgery for histology and scoring, with comprehensive clinical and biochemical assessments before and after the procedure. The aim is to better understand how NAFLD progresses toward more advanced liver disease in this population and identify factors linked to its development. Participants are followed within the surgical care pathway at Prince of Wales Hospital, CUHK, under an institutional lead by CUHK. The study does not assign an intervention beyond standard surgical care, and data collected will help clarify disease progression and potential biomarker signatures.
Why it matters
Potential benefit: Findings could improve understanding of NAFLD progression and identify biomarkers that help predict who is at higher risk for liver disease progression.
How similar studies have gone: Prior research in bariatric populations has shown liver biopsy can reveal NAFLD/NASH features; this study adds longitudinal biomarker assessment in a Chinese cohort.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or above * Chinese ethnicity * Patient undergoing obesity surgery at The Prince of Wales Hospital Exclusion Criteria: * Endocrine causes of obesity * Active uncontrolled psychiatric illness * Active substance abuse * Alcohol intake exceeding 30 grams per day in males or 20 grams per day in females * Presence of other co-existing liver disease, as evidenced by known history of positive viral hepatitis serology * History of decompensated liver disease * Unlikely to comply with management protocol * Failure to give consent
Where it's running
-
Department of Medicine and Therapeutics, The Chinese University of Hong Kong (CUHK), Ward 3M, Diabetes and Endocrine Research Centre, 3/F Day Treatment Block and Children Wards (Old Block), Prince of Wales Hospital
Hong Kong, New Territories, Hong Kong Recruiting
Study contacts
- Study coordinator: Alice Pik Shan Kong, MD
- Email: alicekong@cuhk.edu.hk
- Phone: +852 3505 2648
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Low‑methoxy pectin for inflammation, gut microbiome, and metabolic health in MASLD
This tests whether taking daily low‑methoxy pectin for six weeks can reduce inflammation and improve gut bacteria and metabolic markers in adults with MASLD.
-
Gepaktiv compared with UDCA and Ademetionine for MAFLD with enlarged liver
This study will try the dietary supplement Gepaktiv to see if it improves liver enzymes, liver size, and fat in adults with MAFLD and hepatomegaly compared with UDCA and ademetionine.
-
Using ultrasound techniques to diagnose nonalcoholic steatohepatitis
This study is testing new ultrasound techniques to see if they can accurately diagnose nonalcoholic steatohepatitis in people with fatty liver disease without needing a liver biopsy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.